Literature DB >> 23138176

Ovarian cancer stem cells: working towards the root of stemness.

Rosemary Foster1, Ronald J Buckanovich, Bo R Rueda.   

Abstract

Despite medical advances made over the past decade, ovarian cancer remains one of the more lethal gynecologic cancers in the United States. While current therapeutic strategies are relatively effective, there is a high incidence of recurrent chemoresistant disease. This has been attributed, in part, to a regenerative tumor cell sub-population that has acquired stem cell properties which allows these cells to escape standard chemotherapeutics and drive recurrent disease. To date, a number of laboratories have identified these cancer stem cell (CSC) sub-populations in ovarian cancer cell lines, tumors or ascites and the collective findings suggest ovarian CSCs are likely to be as heterogeneous as the disease itself. Moreover, the multiple ovarian histophenotypes and possible sites of disease origin together with the potential for differential hierarchal contributions of multiple CSCs populations represent significant challenges to the identification, functional characterization and therapeutic targeting of ovarian CSC. This review will highlight the markers and methodology currently used to identify and isolate these cells. We will discuss some of the underlying ovarian CSC biology, the signaling pathways implicated in their survival, replication and differentiation and potential therapeutic targeting strategies.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Ovarian cancer

Mesh:

Substances:

Year:  2012        PMID: 23138176     DOI: 10.1016/j.canlet.2012.10.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  60 in total

1.  Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Authors:  Kibeom Jang; Hyunho Yoon; Karina E Hew; Fiona Simpkins; Minsoon Kim; Diana J Azzam; Jun Sun; Dekuang Zhao; Tan A Ince; Wenbin Liu; Wei Guo; Zhi Wei; Gao Zhang; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2018-06-29       Impact factor: 12.531

2.  Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells.

Authors:  Junjie Li; Salvatore Condello; Jessica Thomes-Pepin; Xiaoxiao Ma; Yu Xia; Thomas D Hurley; Daniela Matei; Ji-Xin Cheng
Journal:  Cell Stem Cell       Date:  2016-12-29       Impact factor: 24.633

3.  Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2.

Authors:  Yun-Jung Choi; Patrick N Ingram; Kun Yang; Lan Coffman; Mangala Iyengar; Shoumei Bai; Dafydd G Thomas; Euisik Yoon; Ronald J Buckanovich
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

4.  Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor.

Authors:  Tiansong Zhang; Linhao Deng; Qian Xiong; Shujun Su; Jian Gu
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

Review 5.  Ovarian cancer stem cells: are they real and why are they important?

Authors:  Monjri M Shah; Charles N Landen
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

6.  Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.

Authors:  Min Peng; Hao Zhang; Lahcen Jaafar; John I Risinger; Shuang Huang; Nahid F Mivechi; Lan Ko
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 7.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

8.  STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.

Authors:  Jennifer Permuth-Wey; William J Fulp; Brett M Reid; Zhihua Chen; Christina Georgeades; Jin Q Cheng; Anthony Magliocco; Dung-Tsa Chen; Johnathan M Lancaster
Journal:  Int J Cancer       Date:  2015-08-28       Impact factor: 7.396

9.  Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer.

Authors:  Yi-Fei Chen; Zhangli Dong; Yi Xia; Jingjie Tang; Ling Peng; Shuying Wang; Dongmei Lai
Journal:  Cancer Sci       Date:  2013-10-22       Impact factor: 6.716

10.  Low-dose cisplatin-induced CXCR4 expression promotes proliferation of ovarian cancer stem-like cells.

Authors:  Yifei Chen; Shuying Wang; Shixia Bu; Minhua Xu; Dongmei Lai
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-01-26       Impact factor: 3.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.